Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan

Published:2023-08-12 Issue:1 Volume:26 Page:1009-1018
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Chandler Conor¹^ORCID,Burnett Heather²^ORCID,Schaible Kassandra¹^ORCID,Senthil Vishnu¹^ORCID,Kato Masafumi³^ORCID,Miura Yuji⁴^ORCID,Osawa Takahiro⁵^ORCID,Uemura Hiroji⁶^ORCID,Kuwabara Hiroyo³^ORCID

Affiliation:

1. Evidera Inc, Waltham, MA, United States of America

2. Evidera Inc, St-Laurent, Canada

3. Market Access, Public Affairs & Patient Experience, Takeda Pharmaceutical Company Ltd, Tokyo, Japan

4. Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan

5. Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan

6. Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan

Funder

Takeda Pharmaceutical Company

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2242197

Reference34 articles.

1. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Comparison of Time Trends in Kidney Cancer Incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII

3. Current management options in metastatic renal cell cancer

4. Japanese Urological Association. Clinical practice guideline for renal cancer (revision of 2017 guidelines) 2017 [September 2020]. Available from: https://www.urol.or.jp/lib/files/other/guideline/33_renal_cancer_2017_rev2019.pdf.

5. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial